Key result
Ampreloxetine shows promise for treating neurogenic orthostatic hypotension but requires large trials to define risks.
Absolute satellite antenna group delay variations can be estimated based on terrestrial observations, revealing significant variations across different satellite constellations and frequencies.
Ampreloxetine may warrant further study in neurogenic orthostatic hypotension; leaves open its risk-benefit profile pending larger trials.
No takes yet. Share an insight, caveat, or question.
Eisenhofer et al. (2021) conducted an editorial in Neurogenic orthostatic hypotension (nOH). Ampreloxetine was evaluated. Ampreloxetine, a novel norepinephrine transporter inhibitor, shows promise for treating neurogenic orthostatic hypotension, though large clinical trials are needed to define its risk/benefit profile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: